{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:51:15Z","timestamp":1791654675850,"version":"4.3.4"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100019413","name":"Yunnan Provincial Department of Education Science Research Fund Project","doi-asserted-by":"crossref","award":["2023J1758"],"award-info":[{"award-number":["2023J1758"]}],"id":[{"id":"10.13039\/501100019413","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019413","name":"Yunnan Provincial Department of Education Science Research Fund Project","doi-asserted-by":"crossref","award":["2024J1607"],"award-info":[{"award-number":["2024J1607"]}],"id":[{"id":"10.13039\/501100019413","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Yunnan Province Joint Special Project for Basic Research of Traditional Chinese Medicine","award":["202301AZ070001-172"],"award-info":[{"award-number":["202301AZ070001-172"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03217-4","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T19:04:26Z","timestamp":1753297466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sirtuin family in lung adenocarcinoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Cui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"3217_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"3217_CR2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S215543","author":"Y Peng","year":"2019","unstructured":"Peng Y, Xu Y, Yang G, et al. Knockdown of long non-coding RNA TP73-AS1 inhibited cell proliferation and metastasis through Wnt\/\u03b2-catenin pathway in lung adenocarcinoma. Onco Targets Ther. 2019. https:\/\/doi.org\/10.2147\/OTT.S215543.","journal-title":"Onco Targets Ther"},{"key":"3217_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00274","author":"A Wang","year":"2017","unstructured":"Wang A, Ning Z, Lu C, et al. USP22 induces cisplatin resistance in lung adenocarcinoma by regulating \u03b3H2AX-mediated DNA damage repair and Ku70\/Bax-mediated apoptosis. Front Pharmacol. 2017. https:\/\/doi.org\/10.3389\/fphar.2017.00274.","journal-title":"Front Pharmacol"},{"key":"3217_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-022-00564-4","author":"H Luan","year":"2022","unstructured":"Luan H, Yan L, Zhao Y, et al. Fucoxanthin induces apoptosis and reverses epithelial-mesenchymal transition via inhibiting Wnt\/\u03b2-catenin pathway in lung adenocarcinoma. Discov Oncol. 2022. https:\/\/doi.org\/10.1007\/s12672-022-00564-4.","journal-title":"Discov Oncol"},{"key":"3217_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102237","author":"L Succony","year":"2021","unstructured":"Succony L, Rassl DM, Barker AP, et al. Adenocarcinoma spectrum lesions of the lung: detection, pathology and treatment strategies. Cancer Treat Rev. 2021. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102237.","journal-title":"Cancer Treat Rev"},{"key":"3217_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713302","author":"Y Song","year":"2023","unstructured":"Song Y, Kelava L, Kiss I. MiRNAs in lung adenocarcinoma: role, diagnosis, prognosis, and therapy. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241713302.","journal-title":"Int J Mol Sci"},{"key":"3217_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13745","author":"Y Huang","year":"2021","unstructured":"Huang Y, Feng G. MiR-423-5p aggravates lung adenocarcinoma via targeting CADM1. Thorac Cancer. 2021. https:\/\/doi.org\/10.1111\/1759-7714.13745.","journal-title":"Thorac Cancer"},{"key":"3217_CR8","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202625","author":"Y Yu","year":"2021","unstructured":"Yu Y, Wang Z, Zheng Q, et al. FAM72 serves as a biomarker of poor prognosis in human lung adenocarcinoma. Aging. 2021. https:\/\/doi.org\/10.18632\/aging.202625.","journal-title":"Aging"},{"key":"3217_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00259","author":"H Hu","year":"2020","unstructured":"Hu H, Xu H, Lu F, et al. Exosome-derived miR-486\u20135p regulates cell cycle, proliferation and metastasis in lung adenocarcinoma via targeting NEK2. Front Bioeng Biotechnol. 2020. https:\/\/doi.org\/10.3389\/fbioe.2020.00259.","journal-title":"Front Bioeng Biotechnol"},{"key":"3217_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116528","author":"Y Yu","year":"2024","unstructured":"Yu Y, Li L, Luo B, et al. Predicting potential therapeutic targets and small molecule drugs for early-stage lung adenocarcinoma. Biomed Pharmacother. 2024. https:\/\/doi.org\/10.1016\/j.biopha.2024.116528.","journal-title":"Biomed Pharmacother"},{"key":"3217_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.724741","author":"XS Liu","year":"2021","unstructured":"Liu XS, Zhou LM, Yuan LL, et al. NPM1 is a prognostic biomarker involved in immune infiltration of lung adenocarcinoma and associated with m6a modification and glycolysis. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.724741.","journal-title":"Front Immunol"},{"key":"3217_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010048","author":"K Yamagata","year":"2023","unstructured":"Yamagata K, Mizumoto T, Yoshizawa T. The emerging role of SIRT7 in glucose and lipid metabolism. Cells. 2023. https:\/\/doi.org\/10.3390\/cells13010048.","journal-title":"Cells"},{"key":"3217_CR13","doi-asserted-by":"publisher","DOI":"10.7150\/thno.100667","author":"H Shen","year":"2024","unstructured":"Shen H, Qi X, Hu Y, et al. Targeting sirtuins for cancer therapy: epigenetics modifications and beyond. Theranostics. 2024. https:\/\/doi.org\/10.7150\/thno.100667.","journal-title":"Theranostics"},{"key":"3217_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/molecules191220295","author":"T Kozako","year":"2014","unstructured":"Kozako T, Suzuki T, Yoshimitsu M, et al. Anticancer agents targeted to sirtuins. Molecules. 2014. https:\/\/doi.org\/10.3390\/molecules191220295.","journal-title":"Molecules"},{"key":"3217_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186231","author":"Z Tao","year":"2023","unstructured":"Tao Z, Jin Z, Wu J, et al. Sirtuin family in autoimmune diseases. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1186231.","journal-title":"Front Immunol"},{"key":"3217_CR16","doi-asserted-by":"publisher","DOI":"10.1159\/000477417","author":"LM Garcia-Peterson","year":"2017","unstructured":"Garcia-Peterson LM, Wilking-Busch MJ, Ndiaye MA, et al. Sirtuins in skin and skin cancers. Skin Pharmacol Physiol. 2017. https:\/\/doi.org\/10.1159\/000477417.","journal-title":"Skin Pharmacol Physiol"},{"key":"3217_CR17","doi-asserted-by":"publisher","DOI":"10.3892\/or.2024.8786","author":"M Zhou","year":"2024","unstructured":"Zhou M, Wei L, Lu R. Emerging role of sirtuins in non-small cell lung cancer (review). Oncol Rep. 2024. https:\/\/doi.org\/10.3892\/or.2024.8786.","journal-title":"Oncol Rep"},{"key":"3217_CR18","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S166946","author":"J Gong","year":"2018","unstructured":"Gong J, Wang H, Lou W, et al. Associations of sirtuins with clinicopathological parameters and prognosis in non-small cell lung cancer. Cancer Manag Res. 2018. https:\/\/doi.org\/10.2147\/CMAR.S166946.","journal-title":"Cancer Manag Res"},{"key":"3217_CR19","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0942","author":"Z Liang","year":"2014","unstructured":"Liang Z, Yang Y, Wang H, et al. Inhibition of SIRT1 signaling sensitizes the antitumor activity of silybin against human lung adenocarcinoma cells in vitro and in vivo. Mol Cancer Ther. 2014. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0942.","journal-title":"Mol Cancer Ther"},{"key":"3217_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00199","author":"LX Luo","year":"2017","unstructured":"Luo LX, Li Y, Liu ZQ, et al. Honokiol induces apoptosis, G1 arrest, and autophagy in KRAS mutant lung cancer cells. Front Pharmacol. 2017. https:\/\/doi.org\/10.3389\/fphar.2017.00199.","journal-title":"Front Pharmacol"},{"key":"3217_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1065-0","author":"S Iachettini","year":"2018","unstructured":"Iachettini S, Trisciuoglio D, Rotili D, et al. Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. Cell Death Dis. 2018. https:\/\/doi.org\/10.1038\/s41419-018-1065-0.","journal-title":"Cell Death Dis"},{"key":"3217_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133153","author":"DK Alves-Fernandes","year":"2019","unstructured":"Alves-Fernandes DK, Jasiulionis MG. The role of SIRT1 on DNA damage response and epigenetic alterations in cancer. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20133153.","journal-title":"Int J Mol Sci"},{"key":"3217_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.682762","author":"R Xu","year":"2021","unstructured":"Xu R, Luo X, Ye X, et al. SIRT1\/PGC-1\u03b1\/PPAR-\u03b3 correlate With hypoxia-induced chemoresistance in non-small cell lung cancer. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.682762.","journal-title":"Front Oncol"},{"key":"3217_CR24","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S82378","author":"C Li","year":"2015","unstructured":"Li C, Wang L, Zheng L, et al. SIRT1 expression is associated with poor prognosis of lung adenocarcinoma. Onco Targets Ther. 2015. https:\/\/doi.org\/10.2147\/OTT.S82378.","journal-title":"Onco Targets Ther"},{"key":"3217_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315119","author":"A Poniewierska-Baran","year":"2022","unstructured":"Poniewierska-Baran A, Warias P, Zgutka K, et al. Sirtuins (SIRTs) as a novel target in gastric cancer. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232315119.","journal-title":"Int J Mol Sci"},{"key":"3217_CR26","doi-asserted-by":"publisher","DOI":"10.16073\/j.cnki.cjcpt.2016.06.003","author":"M Hao","year":"2016","unstructured":"Hao M, Quanqin X, Yun Z, et al. Expression of SIRT1 and its clinical significance in lung adenocarcinoma tissues. Chin J Cancer Prevent Treatment. 2016. https:\/\/doi.org\/10.16073\/j.cnki.cjcpt.2016.06.003.","journal-title":"Chin J Cancer Prevent Treatment"},{"key":"3217_CR27","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2057","author":"X Chen","year":"2014","unstructured":"Chen X, Hokka D, Maniwa Y, et al. Sirt1 is a tumor promoter in lung adenocarcinoma. Oncol Lett. 2014. https:\/\/doi.org\/10.3892\/ol.2014.2057.","journal-title":"Oncol Lett"},{"key":"3217_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14194","author":"BB Lee","year":"2019","unstructured":"Lee BB, Kim Y, Kim D, et al. Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells. J Cell Mol Med. 2019. https:\/\/doi.org\/10.1111\/jcmm.14194.","journal-title":"J Cell Mol Med"},{"key":"3217_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124670","author":"I Grbesa","year":"2015","unstructured":"Grbesa I, Pajares MJ, Mart\u00ednez-Terroba E, et al. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients. PLoS ONE. 2015. https:\/\/doi.org\/10.1371\/journal.pone.0124670.","journal-title":"PLoS ONE"},{"key":"3217_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079162","author":"T Zhang","year":"2013","unstructured":"Zhang T, Rong N, Chen J, et al. SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0079162.","journal-title":"PLoS ONE"},{"key":"3217_CR31","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020117-043854","author":"V Mittal","year":"2018","unstructured":"Mittal V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol. 2018. https:\/\/doi.org\/10.1146\/annurev-pathol-020117-043854.","journal-title":"Annu Rev Pathol"},{"key":"3217_CR32","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1820209","author":"DL Gibbons","year":"2009","unstructured":"Gibbons DL, Lin W, Creighton CJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009. https:\/\/doi.org\/10.1101\/gad.1820209.","journal-title":"Genes Dev"},{"key":"3217_CR33","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-1250","author":"HL Wang","year":"2020","unstructured":"Wang HL, Wang HR, Liang Y, et al. Hsa_circ_0006571 promotes spinal metastasis through sponging microRNA-138 to regulate sirtuin 1 expression in lung adenocarcinoma. Transl Lung Cancer Res. 2020. https:\/\/doi.org\/10.21037\/tlcr-20-1250.","journal-title":"Transl Lung Cancer Res"},{"key":"3217_CR34","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2022.12595","author":"H Liao","year":"2022","unstructured":"Liao H, Ding M, Zhou N, et al. B7\u2013H3 promotes the epithelial-mesenchymal transition of NSCLC by targeting SIRT1 through the PI3K\/AKT pathway. Mol Med Rep. 2022. https:\/\/doi.org\/10.3892\/mmr.2022.12595.","journal-title":"Mol Med Rep"},{"key":"3217_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9140191","author":"M Sun","year":"2021","unstructured":"Sun M, Zhuang X, Lv G, et al. Ginsenoside CK inhibits TGF-\u03b2-induced epithelial-mesenchymal transition in A549 cell via SIRT1. Biomed Res Int. 2021. https:\/\/doi.org\/10.1155\/2021\/9140191.","journal-title":"Biomed Res Int"},{"key":"3217_CR36","doi-asserted-by":"publisher","DOI":"10.2217\/epi-2022-0432","author":"W Peng","year":"2023","unstructured":"Peng W, Jiang J, Fu J, et al. lncRNA GMDS-AS1 restrains lung adenocarcinoma progression via recruiting TAF15 protein to stabilize SIRT1 mRNA. Epigenomics. 2023. https:\/\/doi.org\/10.2217\/epi-2022-0432.","journal-title":"Epigenomics"},{"key":"3217_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0700-1","author":"S Yang","year":"2017","unstructured":"Yang S, Liu Y, Li MY, et al. FOXP3 promotes tumor growth and metastasis by activating Wnt\/\u03b2-catenin signaling pathway and EMT in non-small cell lung cancer. Mol Cancer. 2017. https:\/\/doi.org\/10.1186\/s12943-017-0700-1.","journal-title":"Mol Cancer"},{"key":"3217_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cells11233737","author":"H Wan","year":"2022","unstructured":"Wan H, Lin T, Shan M, et al. LINC00491 facilitates tumor progression of lung adenocarcinoma via Wnt\/\u03b2-catenin-signaling pathway by regulating MTSS1 ubiquitination. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11233737.","journal-title":"Cells"},{"key":"3217_CR39","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12774","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Song T, Peng J, et al. SIRT1 suppresses adipogenesis by activating Wnt\/\u03b2-catenin signaling in vivo and in vitro. Oncotarget. 2016. https:\/\/doi.org\/10.18632\/oncotarget.12774.","journal-title":"Oncotarget"},{"key":"3217_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.10.002","author":"Y Luo","year":"2019","unstructured":"Luo Y, Chen JJ, Lv Q, et al. Long non-coding RNA NEAT1 promotes colorectal cancer progression by competitively binding miR-34a with SIRT1 and enhancing the Wnt\/\u03b2-catenin signaling pathway. Cancer Lett. 2019. https:\/\/doi.org\/10.1016\/j.canlet.2018.10.002.","journal-title":"Cancer Lett"},{"key":"3217_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.12.120","author":"Y Yao","year":"2019","unstructured":"Yao Y, Hua Q, Zhou Y, et al. CircRNA has_circ_0001946 promotes cell growth in lung adenocarcinoma by regulating miR-135a-5p\/SIRT1 axis and activating Wnt\/\u03b2-catenin signaling pathway. Biomed Pharmacother. 2019. https:\/\/doi.org\/10.1016\/j.biopha.2018.12.120.","journal-title":"Biomed Pharmacother"},{"key":"3217_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw808","author":"J Wan","year":"2016","unstructured":"Wan J, Xu W, Zhan J, et al. PCAF-mediated acetylation of transcriptional factor HOXB9 suppresses lung adenocarcinoma progression by targeting oncogenic protein JMJD6. Nucleic Acids Res. 2016. https:\/\/doi.org\/10.1093\/nar\/gkw808.","journal-title":"Nucleic Acids Res"},{"key":"3217_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv238","author":"J An","year":"2015","unstructured":"An J, Zhan J, Li S, et al. PCAF-primed EZH2 acetylation regulates its stability and promotes lung adenocarcinoma progression. Nucleic Acids Res. 2015. https:\/\/doi.org\/10.1093\/nar\/gkv238.","journal-title":"Nucleic Acids Res"},{"key":"3217_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235812","author":"J Ji","year":"2022","unstructured":"Ji J, Wang K, Meng X, et al. Elaiophylin inhibits tumorigenesis of human lung adenocarcinoma by inhibiting mitophagy via suppression of SIRT1\/Nrf2 signaling. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14235812.","journal-title":"Cancers"},{"key":"3217_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209049","author":"H Ota","year":"2006","unstructured":"Ota H, Tokunaga E, Chang K, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 2006. https:\/\/doi.org\/10.1038\/sj.onc.1209049.","journal-title":"Oncogene"},{"key":"3217_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113709","author":"E Roshdy","year":"2021","unstructured":"Roshdy E, Mustafa M, Shaltout AE, et al. Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020. Eur J Med Chem. 2021. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113709.","journal-title":"Eur J Med Chem"},{"key":"3217_CR47","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7816","author":"Z Li","year":"2016","unstructured":"Li Z, Huang J, Yuan H, et al. SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation. Oncotarget. 2016. https:\/\/doi.org\/10.18632\/oncotarget.7816.","journal-title":"Oncotarget"},{"key":"3217_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.05.013","author":"Z Li","year":"2013","unstructured":"Li Z, Xie QR, Chen Z, et al. Regulation of SIRT2 levels for human non-small cell lung cancer therapy. Lung Cancer. 2013. https:\/\/doi.org\/10.1016\/j.lungcan.2013.05.013.","journal-title":"Lung Cancer"},{"key":"3217_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.601953","author":"L Wang","year":"2020","unstructured":"Wang L, Xu P, Xie X, et al. Down regulation of SIRT2 reduced ASS induced NSCLC apoptosis through the release of autophagy components via exosomes. Front Cell Dev Biol. 2020. https:\/\/doi.org\/10.3389\/fcell.2020.601953.","journal-title":"Front Cell Dev Biol"},{"key":"3217_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1007653","author":"J He","year":"2023","unstructured":"He J, Qiu N, Zhou X, et al. Resveratrol analog, triacetylresveratrol, a potential immunomodulator of lung adenocarcinoma immunotherapy combination therapies. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2022.1007653.","journal-title":"Front Oncol"},{"key":"3217_CR51","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12992","author":"M Zheng","year":"2021","unstructured":"Zheng M, Hu C, Wu M, et al. Emerging role of SIRT2 in non-small cell lung cancer. Oncol Lett. 2021. https:\/\/doi.org\/10.3892\/ol.2021.12992.","journal-title":"Oncol Lett"},{"key":"3217_CR52","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2014-0284","author":"W Xu","year":"2015","unstructured":"Xu W, Jiang K, Shen M, et al. SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A. Biol Chem. 2015. https:\/\/doi.org\/10.1515\/hsz-2014-0284.","journal-title":"Biol Chem"},{"key":"3217_CR53","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12015","author":"HY Song","year":"2016","unstructured":"Song HY, Biancucci M, Kang HJ, et al. SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status. Oncotarget. 2016. https:\/\/doi.org\/10.18632\/oncotarget.12015.","journal-title":"Oncotarget"},{"key":"3217_CR54","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0971","author":"B Peck","year":"2010","unstructured":"Peck B, Chen CY, Ho KK, et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther. 2010. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0971.","journal-title":"Mol Cancer Ther"},{"key":"3217_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.01.114","author":"YH Jin","year":"2008","unstructured":"Jin YH, Kim YJ, Kim DW, et al. Sirt2 interacts with 14\u20133-3 beta\/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun. 2008. https:\/\/doi.org\/10.1016\/j.bbrc.2008.01.114.","journal-title":"Biochem Biophys Res Commun"},{"key":"3217_CR56","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.487736","author":"G Hoffmann","year":"2014","unstructured":"Hoffmann G, Breitenb\u00fccher F, Schuler M, et al. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem. 2014. https:\/\/doi.org\/10.1074\/jbc.M113.487736.","journal-title":"J Biol Chem"},{"key":"3217_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-637-5_1","author":"L Guarente","year":"2013","unstructured":"Guarente L. Introduction: sirtuins in aging and diseases. Methods Mol Biol. 2013. https:\/\/doi.org\/10.1007\/978-1-62703-637-5_1.","journal-title":"Methods Mol Biol"},{"key":"3217_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"3217_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25676","author":"TY Alhazzazi","year":"2011","unstructured":"Alhazzazi TY, Kamarajan P, Joo N, et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer. 2011. https:\/\/doi.org\/10.1002\/cncr.25676.","journal-title":"Cancer"},{"key":"3217_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.25653","author":"M Torrens-Mas","year":"2017","unstructured":"Torrens-Mas M, Pons DG, Sastre-Serra J, et al. SIRT3 silencing sensitizes breast cancer cells to cytotoxic treatments through an increment in ROS production. J Cell Biochem. 2017. https:\/\/doi.org\/10.1002\/jcb.25653.","journal-title":"J Cell Biochem"},{"key":"3217_CR61","doi-asserted-by":"publisher","DOI":"10.3892\/or.2013.2604","author":"K Xiao","year":"2013","unstructured":"Xiao K, Jiang J, Wang W, et al. Sirt3 is a tumor suppressor in lung adenocarcinoma cells. Oncol Rep. 2013. https:\/\/doi.org\/10.3892\/or.2013.2604.","journal-title":"Oncol Rep"},{"issue":"19","key":"3217_CR62","first-page":"2379","volume":"41","author":"Q Yongchao","year":"2020","unstructured":"Yongchao Q, Jin M, Aiping Z, et al. Expression of MnSOD and SIRT3 in lung adenocarcinoma and adjacent tissues and its relationship with clinical pathology and prognosis. Int J Laboratory Med. 2020;41(19):2379\u201383.","journal-title":"Int J Laboratory Med"},{"key":"3217_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01649-x","author":"AS Gorbunova","year":"2023","unstructured":"Gorbunova AS, Zamaraev AV, Yapryntseva MA, et al. Prognostic signature based on mitochondria quality control proteins for the prediction of lung adenocarcinoma patients survival. Cell Death Discov. 2023. https:\/\/doi.org\/10.1038\/s41420-023-01649-x.","journal-title":"Cell Death Discov"},{"key":"3217_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3728","author":"Y Cao","year":"2021","unstructured":"Cao Y, Li P, Wang H, et al. SIRT3 promotion reduces resistance to cisplatin in lung cancer by modulating the FOXO3\/CDT1 axis. Cancer Med. 2021. https:\/\/doi.org\/10.1002\/cam4.3728.","journal-title":"Cancer Med"},{"key":"3217_CR65","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12504","author":"K Akamata","year":"2016","unstructured":"Akamata K, Wei J, Bhattacharyya M, et al. SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. Oncotarget. 2016. https:\/\/doi.org\/10.18632\/oncotarget.12504.","journal-title":"Oncotarget"},{"key":"3217_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.14","author":"Y Chen","year":"2014","unstructured":"Chen Y, Fu LL, Wen X, et al. Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death Dis. 2014. https:\/\/doi.org\/10.1038\/cddis.2014.14.","journal-title":"Cell Death Dis"},{"key":"3217_CR67","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2103","author":"H Li","year":"2013","unstructured":"Li H, Feng Z, Wu W, et al. SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non-small cell lung cancer cells through deacetylation of NMNAT2. Int J Oncol. 2013. https:\/\/doi.org\/10.3892\/ijo.2013.2103.","journal-title":"Int J Oncol"},{"key":"3217_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121949","author":"E Zhao","year":"2019","unstructured":"Zhao E, Hou J, Ke X, et al. The roles of sirtuin family proteins in cancer progression. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11121949.","journal-title":"Cancers"},{"key":"3217_CR69","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202803","author":"J Zhang","year":"2021","unstructured":"Zhang J, Han L, Yu J, et al. miR-224 aggravates cancer-associated fibroblast-induced progression of non-small cell lung cancer by modulating a positive loop of the SIRT3\/AMPK\/mTOR\/HIF-1\u03b1 axis. Aging. 2021. https:\/\/doi.org\/10.18632\/aging.202803.","journal-title":"Aging"},{"key":"3217_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12755","author":"X Chen","year":"2021","unstructured":"Chen X, Hao B, Li D, et al. Melatonin inhibits lung cancer development by reversing the Warburg effect via stimulating the SIRT3\/PDH axis. J Pineal Res. 2021. https:\/\/doi.org\/10.1111\/jpi.12755.","journal-title":"J Pineal Res"},{"key":"3217_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175208","author":"G Ren","year":"2022","unstructured":"Ren G, Ma Y, Wang X, et al. Aspirin blocks AMPK\/SIRT3-mediated glycolysis to inhibit NSCLC cell proliferation. Eur J Pharmacol. 2022. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175208.","journal-title":"Eur J Pharmacol"},{"key":"3217_CR72","doi-asserted-by":"publisher","DOI":"10.7150\/thno.45922","author":"J Zhang","year":"2020","unstructured":"Zhang J, Xiang H, Liu J, et al. Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target. Theranostics. 2020. https:\/\/doi.org\/10.7150\/thno.45922.","journal-title":"Theranostics"},{"key":"3217_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7656","author":"VB Pillai","year":"2015","unstructured":"Pillai VB, Samant S, Sundaresan NR, et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nat Commun. 2015. https:\/\/doi.org\/10.1038\/ncomms7656.","journal-title":"Nat Commun"},{"key":"3217_CR74","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12419","author":"M Zhai","year":"2017","unstructured":"Zhai M, Li B, Duan W, et al. Melatonin ameliorates myocardial ischemia reperfusion injury through SIRT3-dependent regulation of oxidative stress and apoptosis. J Pineal Res. 2017. https:\/\/doi.org\/10.1111\/jpi.12419.","journal-title":"J Pineal Res"},{"key":"3217_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00178","author":"Y Li","year":"2017","unstructured":"Li Y, Ye Z, Lai W, et al. Activation of Sirtuin 3 by silybin attenuates mitochondrial dysfunction in cisplatin-induced acute kidney Injury. Front Pharmacol. 2017. https:\/\/doi.org\/10.3389\/fphar.2017.00178.","journal-title":"Front Pharmacol"},{"key":"3217_CR76","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7296092","author":"S Xu","year":"2016","unstructured":"Xu S, Gao Y, Zhang Q, et al. SIRT1\/3 activation by resveratrol attenuates acute kidney injury in a septic rat model. Oxid Med Cell Longev. 2016. https:\/\/doi.org\/10.1155\/2016\/7296092.","journal-title":"Oxid Med Cell Longev"},{"key":"3217_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2016.09.003","author":"M Zhang","year":"2017","unstructured":"Zhang M, Zhao Z, Shen M, et al. Polydatin protects cardiomyocytes against myocardial infarction injury by activating Sirt3. Biochim Biophys Acta Mol Basis Dis. 2017. https:\/\/doi.org\/10.1016\/j.bbadis.2016.09.003.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"3217_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.nutres.2015.06.014","author":"J Zhang","year":"2015","unstructured":"Zhang J, Meruvu S, Bedi YS, et al. Pyrroloquinoline quinone increases the expression and activity of Sirt1 and -3 genes in HepG2 cells. Nutr Res. 2015. https:\/\/doi.org\/10.1016\/j.nutres.2015.06.014.","journal-title":"Nutr Res"},{"key":"3217_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/biom8030044","author":"RI Khan","year":"2018","unstructured":"Khan RI, Nirzhor SSR, Akter R. A review of the recent advances made with SIRT6 and its implications on aging related processes, major human diseases, and possible therapeutic targets. Biomolecules. 2018. https:\/\/doi.org\/10.3390\/biom8030044.","journal-title":"Biomolecules"},{"key":"3217_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23975","author":"Y Azuma","year":"2015","unstructured":"Azuma Y, Yokobori T, Mogi A, et al. SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer. J Surg Oncol. 2015. https:\/\/doi.org\/10.1002\/jso.23975.","journal-title":"J Surg Oncol"},{"key":"3217_CR81","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-022-01751-y","author":"Q You","year":"2022","unstructured":"You Q, Wang J, Yu Y, et al. The histone deacetylase SIRT6 promotes glycolysis through the HIF-1\u03b1\/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer. Apoptosis. 2022. https:\/\/doi.org\/10.1007\/s10495-022-01751-y.","journal-title":"Apoptosis"},{"key":"3217_CR82","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9750","author":"L Bai","year":"2016","unstructured":"Bai L, Lin G, Sun L, et al. Upregulation of SIRT6 predicts poor prognosis and promotes metastasis of non-small cell lung cancer via the ERK1\/2\/MMP9 pathway. Oncotarget. 2016. https:\/\/doi.org\/10.18632\/oncotarget.9750.","journal-title":"Oncotarget"},{"key":"3217_CR83","doi-asserted-by":"publisher","DOI":"10.18632\/aging.101958","author":"Y Cai","year":"2019","unstructured":"Cai Y, Sheng Z, Chen Y, et al. LncRNA HMMR-AS1 promotes proliferation and metastasis of lung adenocarcinoma by regulating MiR-138\/sirt6 axis. Aging. 2019. https:\/\/doi.org\/10.18632\/aging.101958.","journal-title":"Aging"},{"key":"3217_CR84","unstructured":"Han Z, Liu L, Liu Y, et al (2014) Sirtuin SIRT6 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer. Int J Clin Exp Pathol. 2014;7(8):4774\u201381."},{"key":"3217_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/iub.2511","author":"L Xiong","year":"2021","unstructured":"Xiong L, Tan B, Lei X, et al. SIRT6 through PI3K\/Akt\/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression. IUBMB Life. 2021. https:\/\/doi.org\/10.1002\/iub.2511.","journal-title":"IUBMB Life"},{"key":"3217_CR86","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00601","author":"F Fiorentino","year":"2021","unstructured":"Fiorentino F, Mai A, Rotili D. Emerging therapeutic potential of SIRT6 modulators. J Med Chem. 2021. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00601.","journal-title":"J Med Chem"},{"key":"3217_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01265","author":"Z Yang","year":"2020","unstructured":"Yang Z, Huang R, Wei X, et al. The SIRT6-autophagy-warburg effect axis in papillary thyroid cancer. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.01265.","journal-title":"Front Oncol"},{"key":"3217_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0984-z","author":"Z Li","year":"2018","unstructured":"Li Z, Huang J, Shen S, et al. SIRT6 drives epithelial-to-mesenchymal transition and metastasis in non-small cell lung cancer via snail-dependent transrepression of KLF4. J Exp Clin Cancer Res. 2018. https:\/\/doi.org\/10.1186\/s13046-018-0984-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"3217_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110629","author":"P Subramani","year":"2023","unstructured":"Subramani P, Nagarajan N, Mariaraj S, et al. Knockdown of sirtuin6 positively regulates acetylation of DNMT1 to inhibit NOTCH signaling pathway in non-small cell lung cancer cell lines. Cell Signal. 2023. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110629.","journal-title":"Cell Signal"},{"key":"3217_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01491-0","author":"T Liu","year":"2020","unstructured":"Liu T, Zhu J, Du W, et al. AKT2 drives cancer progression and is negatively modulated by miR-124 in human lung adenocarcinoma. Respir Res. 2020. https:\/\/doi.org\/10.1186\/s12931-020-01491-0.","journal-title":"Respir Res"},{"key":"3217_CR91","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17464","author":"YH Liu","year":"2022","unstructured":"Liu YH, Yuan M, Xu BX, et al. ANKRD49 promotes the invasion and metastasis of lung adenocarcinoma via a P38\/ATF-2 signalling pathway. J Cell Mol Med. 2022. https:\/\/doi.org\/10.1111\/jcmm.17464.","journal-title":"J Cell Mol Med"},{"key":"3217_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2020.04.027","author":"V Krishnamoorthy","year":"2020","unstructured":"Krishnamoorthy V, Vilwanathan R. Silencing Sirtuin 6 induces cell cycle arrest and apoptosis in non-small cell lung cancer cell lines. Genomics. 2020. https:\/\/doi.org\/10.1016\/j.ygeno.2020.04.027.","journal-title":"Genomics"},{"key":"3217_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166815","author":"Y You","year":"2023","unstructured":"You Y, Liang W. SIRT1 and SIRT6: the role in aging-related diseases. Biochim Biophys Acta Mol Basis Dis. 2023. https:\/\/doi.org\/10.1016\/j.bbadis.2023.166815.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"3217_CR94","first-page":"1575","volume":"11","author":"Y Cai","year":"2018","unstructured":"Cai Y, Sheng Z, Chen Y, et al. Influence of SIRT6 regulation of cellular glycometabolism on radiosensitivity of non-small-cell lung cancer A549 cells. Int J Clin Exp Pathol. 2018;11(3):1575\u201380.","journal-title":"Int J Clin Exp Pathol"},{"key":"3217_CR95","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-141","author":"W Fang","year":"2020","unstructured":"Fang W, Huang Y, Gu W, et al. PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. Transl Lung Cancer Res. 2020. https:\/\/doi.org\/10.21037\/tlcr-20-141.","journal-title":"Transl Lung Cancer Res"},{"key":"3217_CR96","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000709","author":"X Zhou","year":"2019","unstructured":"Zhou X, Zhou R, Li Q, et al. Cardamonin inhibits the proliferation and metastasis of non-small-cell lung cancer cells by suppressing the PI3K\/Akt\/mTOR pathway. Anticancer Drugs. 2019. https:\/\/doi.org\/10.1097\/CAD.0000000000000709.","journal-title":"Anticancer Drugs"},{"key":"3217_CR97","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-6218","author":"ZF Yuan","year":"2023","unstructured":"Yuan ZF, Lin YD, Wu GS, et al. Inhibition of the AKT1\/mTOR pathway through SIRT6 over expression downregulated the expression of programmed death-ligand 1 and prolonged overall survival in lung adenocarcinoma. Ann Transl Med. 2023. https:\/\/doi.org\/10.21037\/atm-22-6218.","journal-title":"Ann Transl Med"},{"key":"3217_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201610082","author":"W You","year":"2017","unstructured":"You W, Rotili D, Li TM, et al. Structural basis of sirtuin 6 activation by synthetic small molecules. Angew Chem Int Ed Engl. 2017. https:\/\/doi.org\/10.1002\/anie.201610082.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3217_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0442-2","author":"JL Shang","year":"2021","unstructured":"Shang JL, Ning SB, Chen YY, et al. MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer. Acta Pharmacol Sin. 2021. https:\/\/doi.org\/10.1038\/s41401-020-0442-2.","journal-title":"Acta Pharmacol Sin"},{"key":"3217_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.425","author":"L Fu","year":"2017","unstructured":"Fu L, Dong Q, He J, et al. SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway. Oncogene. 2017. https:\/\/doi.org\/10.1038\/onc.2016.425.","journal-title":"Oncogene"},{"key":"3217_CR101","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-020-1914-3","author":"S Yang","year":"2022","unstructured":"Yang S, Xu W, Liu C, et al. LATS1 K751 acetylation blocks activation of Hippo signalling and switches LATS1 from a tumor suppressor to an oncoprotein. Sci China Life Sci. 2022. https:\/\/doi.org\/10.1007\/s11427-020-1914-3.","journal-title":"Sci China Life Sci"},{"key":"3217_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e39743","author":"W Shouhan","year":"2024","unstructured":"Shouhan W, Qingchang L, et al. SIRT5 participates in the suppressive tumor immune microenvironment of EGFR-mutant LUAD by regulating the succinylation of ACAT1. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e39743.","journal-title":"Heliyon"},{"issue":"11","key":"3217_CR103","doi-asserted-by":"publisher","first-page":"10699","DOI":"10.1007\/s13277-014-2372-4","volume":"35","author":"W Lu","year":"2014","unstructured":"Lu W, Zuo Y, Feng Y, Zhang M. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. Tumour Biol. 2014;35(11):10699\u2013705. https:\/\/doi.org\/10.1007\/s13277-014-2372-4.","journal-title":"Tumour Biol"},{"key":"3217_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00279-8","author":"J Wu","year":"2021","unstructured":"Wu J, Zheng C, Wang Y, et al. Correction to: LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322\/miR-1972\/ miR-324-3p-SIRT5 axis in lung adenocarcinoma. Biomark Res. 2021. https:\/\/doi.org\/10.1186\/s40364-021-00279-8.","journal-title":"Biomark Res"},{"key":"3217_CR105","doi-asserted-by":"publisher","DOI":"10.3892\/or.2016.5063","author":"H Shi","year":"2016","unstructured":"Shi H, Ji Y, Zhang D, et al. MicroRNA-3666-induced suppression of SIRT7 inhibits the growth of non-small cell lung cancer cells. Oncol Rep. 2016. https:\/\/doi.org\/10.3892\/or.2016.5063.","journal-title":"Oncol Rep"},{"key":"3217_CR106","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7672","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Ye X, Chen R, et al. Sirtuin 7 promotes non-small cell lung cancer progression by facilitating G1\/S phase and epithelial-mesenchymal transition and activating AKT and ERK1\/2 signaling. Oncol Rep. 2020. https:\/\/doi.org\/10.3892\/or.2020.7672.","journal-title":"Oncol Rep"},{"issue":"1","key":"3217_CR107","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbrc.2018.10.089","volume":"506","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Han Z, Wang Y, et al. (2018) Depletion of SIRT7 sensitizes human non-small cell lung cancer cells to gemcitabine therapy by inhibiting autophagy. Biochem Biophys Res Commun. 2018;506(1):266\u201371. https:\/\/doi.org\/10.1016\/j.bbrc.2018.10.089.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03217-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03217-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03217-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T19:04:28Z","timestamp":1753297468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03217-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3217"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03217-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1398"}}